VEGFD and lymphangioleiomyomatosis: The observed LAM progression despite suppressed estrogen levels points towards potential genetic or molecular alterations within LAM cells or the involvement of other hormonal or growth factor pathways, such as VEGF-D, which was elevated in this patient.